ReviewEuroasian journal of hepato-gastroenterology
Hepatocellular Carcinoma in Asia: A Challenging Situation.
Review in Euroasian journal of hepato-gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies.International journal of molecular sciences · 2024Pooled it
- A Scoping Review and Risk Assessment of Aflatoxin B1 Contamination in Rice, Maize, and Peanut-Based Products Across Selected ASEAN Countries.Foods (Basel, Switzerland) · 2026Review
- GBA3 as a regulator of sphingolipid metabolism in the progression of hepatocellular carcinoma.Journal of gastrointestinal oncology · 2025Article
- Hepatocellular Carcinoma Surveillance and Survival in a Contemporary Asia-Pacific Cohort.JAMA network open · 2025Article
- Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studies.JHEP reports : innovation in hepatology · 2025Article
- An Artificial Intelligence Pipeline for Hepatocellular Carcinoma: From Data to Treatment Recommendations.International journal of general medicine · 2025Review
- Absorption, metabolism, and excretion of oral [Cancer chemotherapy and pharmacology · 2024Article
- Attributable liver cancer deaths and disability-adjusted life years in China and worldwide: profiles and changing trends.Cancer biology & medicine · 2024Article
- Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study.Liver cancer · 2024Article
- Applying ONCO-RADS to whole-body MRI cancer screening in a retrospective cohort of asymptomatic individuals.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- The Epidemiology, Transmission, Genotypes, Replication, Serologic and Nucleic Acid Testing, Immunotolerance, and Reactivation of Hepatitis B Virus.Gastro hep advances · 2024Review
- Alcohol-induced liver injury in signalling pathways and curcumin's therapeutic potential.Toxicology reports · 2023Review
- Article
- Molecular Design, Spectroscopic, DFT, Pharmacological, and Molecular Docking Studies of Novel Ruthenium(III)-Schiff Base Complex: An Inhibitor of Progression in HepG2 Cells.International journal of environmental research and public health · 2022Article
- Review
- Testis-specific protein Y-encoded 1 regulates androgen receptor expression through the MAPK/ERK pathway in male hepatocellular carcinoma.Saudi medical journal · 2022Article
- Review
- Inhibition of anti-inflammatory pathway through suppressors of cytokine signalling (Socs2/Socs3) in the initiation of hepatocellular carcinoma.Saudi journal of biological sciences · 2022Article
- Construction and validation of a prognostic marker and risk model for HCC ultrasound therapy combined with WGCNA identification.Frontiers in genetics · 2022Article
- The Combination of Age, International Standardized Ratio, Albumin and γ-Glutamyl Transpeptidase (AIAG), Tumor Size and Alpha Fetoprotein (AFP) Stage as the Prognostic Model for Hepatitis B-Related Hepatocellular Carcinoma.International journal of general medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amongst the primary tumors of the liver, hepatocellular carcinoma (HCC) is the most common. It is also one of the most prevalent types of cancers in Asia. Mostly, HCC occurs on a background of chronic liver disease and liver cirrhosis; however, de novo HCCs can also arise in apparently normal looking livers on imaging. There are multiple risk factors for HCC, including hepatitis B and C infections, diabetes mellitus, alcohol, and nonalcoholic steatohepatitis. Other common risk factors which are known to be involved in the pathogenesis of HCC are obesity, food contaminated with aflatoxin and hemochromatosis. Many of these factors are commonly found in this part of the world, hence the high burden of disease. Besides these, smoking and familial predisposition to HCC also seem to have an important role to play in its development. Majority of HCC are missed at an early stage despite the emphasis on adequate screening and surveillance strategies. Therefore, most of the time these tumors are diagnosed at a fairly advanced stage, when palliative treatment is the only therapeutic option left. Hence, prevention of HCC by controlling and minimizing the possible risk factors is the need of the hour.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.